Bortezomib - In the light of the 2004 Nobel Prize. New perspectives in multiple myeloma treatment;Bortezomib - W świetle Nagrody Nobla 2004. Nowe perspektywy leczenia szpiczaka mnogiego

Wspolczesna Onkologia

Volumn 9, Issue 2, 2005, Pages 54-60

  Krzemieniecki, Krzysztof ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Apoptosis; Bortezomib; Proteasome; Resistant refractory multiple myeloma

Indexed keywords

BORTEZOMIB; CELL PROTEIN; CYTOSTATIC AGENT; PROTEASOME; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR;

ACHIEVEMENT; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CHRONIC PAIN; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; PROTEIN DEGRADATION; PROTEIN FUNCTION; QUALITY OF LIFE; RESEARCH; SALVAGE THERAPY; SOLID TUMOR; TRANSCRIPTION INITIATION; TREATMENT FAILURE;

EID: 18344390868     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79 (1): 13-21.
2. Hershko A, Ciechanover A, Rose IA. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981; 256 (4): 1525-8.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
4. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997; 9 (6): 788-99.
5. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002; 56 (5): 223-34.
6. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843-7.
7. Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol 2004; 5: 430-42.
8. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for MM: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-42.
9. Pandit S, Vesole DH. Relapsed multiple myeloma. Curr Treat Options Oncol 2001; 2: 261-9.
10. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-71.
11. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
12. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 890-6.
13. Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
14. Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002; 30: 873-8.
15. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
16. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-7.
17. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-4.
18. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
19. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-76.
20. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
21. Bross PF, Kane R, Farrel AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954-64.
22. Jagannath S, Barolgie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-72.
23. Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 9: 278-9.
24. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4 (2).